Retlirafusp Alfa

Phase 2

TTang-Du Hospital

Retlirafusp Alfa is one of 142 therapeutic programs targeting Gastric Adenocarcinoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

141

Competitors

Pipeline

Status by Indication[2][1]

Indication

Gastric AdenocarcinomaNot yet recruiting

Triple Negative Breast Cancer (TNBC)Not yet recruiting

Esophageal CancerNot yet recruiting

Pancreatic CancerNot yet recruiting

Colorectal CarcinomaNot yet recruiting

Gastric AdenocarcinomaPhase 2

Not yet recruiting

Triple Negative Breast Cancer (TNBC)Phase 2

Not yet recruiting

Esophageal CancerPhase 2

Not yet recruiting

Pancreatic CancerPhase 2

Not yet recruiting

Colorectal CarcinomaPhase 2

Not yet recruiting

Competition

Competitive Landscape

335 competitors in Pancreatic Cancer

#DrugCompanyPhaseTrials

Retlirafusp Alfa

TTang-Du Hospital

Phase 2

1 2

Byetta

AstraZeneca

Preclinical

1 3

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

1 4

Xylocaine

MMEDRx USA, Inc.

Preclinical

1 5

Feraheme

AAzurity Pharmaceuticals

Preclinical

1 6

Active Comparator

Moderna

Preclinical

1 7

Sulfonylureas

Eli Lilly

Preclinical

1 8

HS-20093

Jiangsu Hansoh Pharmaceutical Co., Ltd.

Preclinical

1 9

Hyperpolarized 13c Pyruvate

UUniversity of Maryland, Baltimore

Preclinical

1 10

PEG-Rhg-CSF

CCSPC Baike (Shandong) Biopharmaceutical Co., Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 2Not yet recruiting

Pancreatic Cancer

NCT07773363

Q1 2029

Phase 2Not yet recruiting

Esophageal Cancer

NCT07770672

Q3 2029

Phase 2Not yet recruiting

Triple Negative Breast Cancer (TNBC)

NCT07752550

Q4 2029

Phase 2Not yet recruiting

Colorectal Carcinoma

NCT07797244

Clinical

Trials by Indication[1]

Colorectal Carcinoma1 trial

A Single-Arm, Phase II Study of Retlirafusp Alfa in Combination With XELOX and Bevacizumab for the First-Line Treatment of Advanced RAS-Mutated Colorectal Cancer With Liver Metastases (CRLM)

Not yet recruiting·DDai, Guanghai·Phase 2·NCT07797244·46 enrolled

Pancreatic Cancer1 trial

A Prospective, Open-Label, Single-Arm Clinical Study of Retlirafusp Alfa Combined With Apatinib and Chemotherapy as Second-Line Treatment for Locally Advanced or Metastatic Pancreatic Cancer

Not yet recruiting·TTang-Du Hospital·Phase 2·NCT07773363·37 enrolled

Esophageal Cancer1 trial

An Exploratory Clinical Study of Accurate Efficacy Assessment of Neoadjuvant Immunotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma Based on 68Ga-FAPI ([68Ga] Fibroblast Activation Protein Inhibitor)/¹⁸F-FDG (2-Deoxy-2-[¹⁸F]Fluoro-D-glucose) Dual Imaging

Not yet recruiting·TTan Lijie·Phase 2·NCT07770672·92 enrolled

Triple Negative Breast Cancer (TNBC)1 trial

Retlirafusp Alfa Combined With Chemotherapy or Fuzuloparib for Triple-Negative Breast Cancer: An Exploratory Clinical Study

Not yet recruiting·HHarbin Medical University·Phase 2·NCT07752550·120 enrolled

Gastric Adenocarcinoma1 trial

A Single-Arm, Exploratory Study of Retlirafusp Alfa Plus Chemotherapy as Conversion Therapy for Gastric or Gastroesophageal Junction Adenocarcinoma

Not yet recruiting·TTang-Du Hospital·Phase 2·NCT07709767·21 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Retlirafusp Alfa. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Retlirafusp Alfa. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Tang-Du Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 2[1]
Company: TTang-Du Hospital

Retlirafusp Alfa

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q4 2028

Q1 2029

Q3 2029

Q4 2029

Trials by Indication[1]

Colorectal Carcinoma1 trial

Pancreatic Cancer1 trial

Esophageal Cancer1 trial

Triple Negative Breast Cancer (TNBC)1 trial

Gastric Adenocarcinoma1 trial

References

Drug Info

Quick Facts

Related News